The OSI-906, a dual kinase inhibitor of both IGF-1R and insulin receptor was evaluated in combination with CTX among patients with HNSCC (NCT01427205, phase 2), but results are not available. The gene discussed is IGF1R; the disease is head and neck squamous cell carcinoma.